Oncology has almost unlimited opportunties to improve measurement in tissues. This ranges from biomarker development of novel markers to the clinical widely used biomarkers of ER, PR, and HER2.
We offer tissue microarray analysis with pathologist review in early stage biomarker research and also in retrospective patient stratification biomarker analysis. We have substantial experience in developing tumor/stroma automated identification solutions, as well as differentiation of cancer cell types in complex tumors found in lung or prostate.
Xenografts are particularly amenable to image analysis automation, and usually includes classifying neoplastic, normal, and necrotic tumor, then running cell analysis for biomarkers or microvessel analysis in angiogenesis inhibitor studies.
We also support oncology clinical trials, and can centralize pathology review in a secure 3rd party “cloud hosted” solution.
Finally, we are active in the IVDMIA area, and can help bring collaborative biostatistics resources to bear in approaches for multi-biomarker solutions.